NetworkNewsBreaks – Predictive Oncology (NASDAQ:
Post# of 281
(Total Views: 191)
Posted On: 10/06/2020 3:58:15 PM
NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Shareholder Letter Provides Company Update, Status of Subsidiaries
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released a shareholder letter providing a review of where POAI “stands as of today.” The letter noted that, despite a decline of stock price over the past few weeks, the company’s cash burn is stable and even trending down, and revenues are stable and trending upward. The letter notes that POAI has adequate cash for operation, as well as ability to utilize an equity line of credit of more than $10 million. The letter also provides an update on the company’s divisions: Skyline Medical, Helomics, TumorGenesis and Soluble Biotech. The letter notes that Skyline Medical is self-supporting from a cash standpoint. Helomics has launched a restructured clinical test offering to clinicians for ovarian cancer. TumorGenesis will be introducing its Ovarian Cell Line Media at the upcoming BIO-Europe Conference; the media allows researchers to isolate and successfully culture ovarian cancer cells that have previously not been cultured. Soluble Biotech has moved into a new facility that effectively quadruples its office and research space. “As you can see, a lot is happening,” said Predictive Oncology CEO Carl Schwartz in the letter. “Much is occurring under the radar. Much doesn’t make for a press release. However, don’t be discouraged by the lack of ‘blockbuster’ announcements. We are moving forward rapidly, and we expect the fourth quarter to be eventful.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released a shareholder letter providing a review of where POAI “stands as of today.” The letter noted that, despite a decline of stock price over the past few weeks, the company’s cash burn is stable and even trending down, and revenues are stable and trending upward. The letter notes that POAI has adequate cash for operation, as well as ability to utilize an equity line of credit of more than $10 million. The letter also provides an update on the company’s divisions: Skyline Medical, Helomics, TumorGenesis and Soluble Biotech. The letter notes that Skyline Medical is self-supporting from a cash standpoint. Helomics has launched a restructured clinical test offering to clinicians for ovarian cancer. TumorGenesis will be introducing its Ovarian Cell Line Media at the upcoming BIO-Europe Conference; the media allows researchers to isolate and successfully culture ovarian cancer cells that have previously not been cultured. Soluble Biotech has moved into a new facility that effectively quadruples its office and research space. “As you can see, a lot is happening,” said Predictive Oncology CEO Carl Schwartz in the letter. “Much is occurring under the radar. Much doesn’t make for a press release. However, don’t be discouraged by the lack of ‘blockbuster’ announcements. We are moving forward rapidly, and we expect the fourth quarter to be eventful.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)